@article{2d54d087c6974736adb465439afc3bc3,
title = "Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era",
abstract = "Hepatic encephalopathy (HE) is a common complication of cirrhosis resulting in relapsing-remitting mental status changes ranging from deficits in executive function to coma. Incident HE is associated with an abrupt increase in mortality1 and frequent hospitalization.2 To further the understanding of the burden and impact of HE at the population level, valid algorithms are required to identify patients in administrative data. An International Classification of Diseases (ICD)-9 code is specific for HE (572.2), offering a 0.92 positive predictive value (PPV) and 0.36 negative predictive value (NPV).3 When applied in an algorithm to patients with ICD-9 codes for cirrhosis (eg, 571.5), Kanwal et al4 found a PPV and NPV of 0.86 and 0.87. Unfortunately, the switch to ICD-10 in 2015 rendered algorithms validated using ICD-9 invalid. Kaplan et al5 previously showed that lactulose and rifaximin use correlated with grade of HE for Child classification. Herein, we validate a diagnostic coding algorithm for HE using ICD-10 and medication records.",
author = "Tapper, {Elliot B.} and Sophia Korovaichuk and Jad Baki and Sydni Williams and Samantha Nikirk and Waljee, {Akbar K.} and Parikh, {Neehar D.}",
note = "Funding Information: Funding Elliot Tapper receives funding from the National Institutes of Health (K23DK117055). Dr. Waljee was supported (or supported in part) by Merit Review Award (IIR 16-024) from the U.S. Department of Veterans Affairs Health Services R&D Service. The views expressed in this article are those of the authors and do not necessarily represent the views of the National Institutes of Health Department of Veterans Affairs. Conflicts of interest This author discloses the following: Elliot Tapper has served as a consultant to Norvartis and Allergan; has served on advisory boards for Mallinckrodt and Bausch Health; and has received unrestricted research grants from Gilead and Valeant. Valeant is the maker of Rifaximin, a medication approved for treatment of hepatic encephalopathy. The remaining authors disclose no conflicts. Funding Information: Funding Elliot Tapper receives funding from the National Institutes of Health ( K23DK117055 ). Dr. Waljee was supported (or supported in part) by Merit Review Award (IIR 16-024) from the U.S. Department of Veterans Affairs Health Services R&D Service. The views expressed in this article are those of the authors and do not necessarily represent the views of the National Institutes of Health Department of Veterans Affairs. Publisher Copyright: {\textcopyright} 2021 AGA Institute",
year = "2021",
month = mar,
doi = "10.1016/j.cgh.2019.12.017",
language = "English (US)",
volume = "19",
pages = "604--606.e1",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "3",
}